ArticleFrontiers in medicine2026
Stress hyperglycemia ratio (SHR) and triglyceride-glucose index (TYG) associated with renal response to finerenone in diabetic kidney disease: a retrospective cohort study.
Article in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Diabetic kidney disease (DKD) is a major complication of type 2 diabetes mellitus (T2DM) and a leading cause of end-stage kidney disease (ESKD). This study aimed to investigate the association between stress hyperglycemia ratio (SHR) and triglyceride-glucose (TyG) index with renal outcomes in patients with Chronic Kidney Disease (CKD) initiating finerenone therapy. Methods: This retrospective cohort study included 387 adults with DKD and CKD stages 1-4 who initiated finerenone therapy between January 2023 and December 2025. The primary composite renal endpoint included sustained ≥40% eGFR decline or progression to ESKD. Secondary outcomes were absolute UACR change at 12 months and annualized eGFR decline rate. Cox proportional hazards models evaluated their associations with renal outcomes, adjusted for clinical covariates. Results: The primary endpoint was reached by 62 patients (16.0%). Higher baseline SHR and TyG were associated with worse renal outcomes. In multivariable analysis, the highest SHR tertile (T3) had a 2.52-fold increased risk (95% CI 1.48-4.29; Conclusion: Higher SHR and TyG values were independently associated with worse renal outcomes in patients with DKD initiating finerenone therapy. These biomarkers could enhance predictive models and inform targeted interventions.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.